Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3366427 | 0.77 | HSD17B10 (0.46) | HSD17B10GLAKDM4EALDH1A1 | |
| SCHEMBL28826935 | 0.76 | — | — | |
| SCHEMBL4320380 | 0.64 | HSD17B10 (0.42) | HSD17B10GLAALDH1A1 | |
| SCHEMBL18557263 | 0.63 | HSD17B10 (0.35) | HSD17B10 | |
| SCHEMBL6092292 | 0.63 | CYP2C19 (0.36) | HSD17B10ALDH1A1 | |
| SCHEMBL9551587 | 0.62 | GRIN1 (0.31) | — | |
| SCHEMBL30619494 | 0.60 | MAPT (0.34) | HSD17B10KDM4EALDH1A1 | |
| SCHEMBL3865584 | 0.59 | HSD17B10 (0.40) | HSD17B10ALDH1A1 | |
| SCHEMBL31609094 | 0.59 | FTO (0.35) | HSD17B10ALDH1A1 | |
| SCHEMBL9193218 | 0.58 | HSD17B10 (0.95) | HSD17B10GLAKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069325-A1 | Piperidine Derivatives Useful as Modulators of Chemokine Receptor Activity | ASTRAZENECA AB (SE) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069325-A1 | Piperidine Derivatives Useful as Modulators of Chemokine Receptor Activity | CCR3, CCR1, CCR5 | HSD17B10 4007/4885GLA 4836/4885KDM4E 3739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.